Bydureon | ASweetLife

The GLP-1 Agonist Debate: How Safe Are Victoza and Bydureon?

The two GLP-1 treatments available are sold under the brand names Byetta and Victoza. The drugs, however, are not very popular with consumers, and are not nearly as popular as they deserve to be, according to Edelman. “It’s a case of clinical inertia on behalf of doctors,” Edelman says regarding one reason why more GLP-1 prescriptions aren’t being written.

My Wake Up Call: Bydureon and Possible Cancer Risk?

Last week, I attended the Second Annual Diabetes Symposium at the Thomas Jefferson University. Surrounded by endocrinologists, nutritionists…

FDA To Re-Evaluate Type 2 Diabetes Drugs Following New Research

The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.

Amylin’s New Type 2 Diabetes Treatment, Bydureon, Now Available in US Pharmacies

The newly approved type 2 diabetes drug Bydureon, made by Amylin Pharmaceuticals and Alkermes plc, is now available by prescription in U.S. pharmacies. Bydureon is the first and only once-weekly treatment for type 2 diabetes. It was approved by the US FDA ...

FDA Approves Type 2 Diabetes Drug Bydureon

Amylin Pharmaceuticals, Inc. and Alkermes plc received FDA approval for Bydureon, a next generation once-weekly treatment for type 2 diabetes. The drug which received EU approval in June was turned down by the FDA twice during 2010, requesting further testing be conducted...

Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...

New Type 2 Diabetes Drug, Bydureon, Shows Positive Effect on A1c and Weight

Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating Bydureon (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the...

Lilly and Amylin Type 2 Diabetes Drug, Bydureon, Approved for Marketing in Europe

The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes' type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients...

Bydureon Receives Positive Opinion From The European Medicines Agency

Eli Lilly and Company, Amylin Pharmaceuticals and Alkermes announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Bydureon for injection in the European Union for the treatment of type 2 diabetes in combination with...

Positive Results for Once Monthly Type 2 Diabetes Drug

Positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes were announced by Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. Exenatide once monthly is a new...